Firering Strategic Minerals: From explorer to producer. Watch the video here.
Imaging Biometrics
IB provides advanced imaging software used by cancer hospitals and universities in the US such as the Mayo Clinic and Stanford University Medical Centre. One application is commercialising aids in the detection and staging of chronic liver disease, while another “leverages deep learning algorithms” for breast cancer screening.
Its software could become part of the consensus methodology for brain tumour diagnosis and treatment, according to an award-winning research article published in March.
Developments and new products
market maybe currently not agreeing, investors have been buying @ sub 3p so we are seeing alot of profit taking imho, this will settle & the news will sink in, for iqai this is a transformational game changer gla
Still in Brazil, another vaccine is under development to prevent Covid-19 infection. Named Versamune®-CoV-2FC, the vaccine is developed by Farmacore - a company founded in 2005 and located in Ribeirão Preto (SP) - in partnership with PDS Biotechnology Corporation . The preliminary results are expected to be completed by the end of July.
Before being approved, the vaccine must go through important stages until it is approved. After the pre-clinical phase, with tests on animals, there are three phases of tests on humans. The tests need to prove that the vaccine is really safe, that it produces antibodies and protects against the virus.
As the pre-clinical and clinical phase I / IIa trials will be carried out in Brazil, the expectation is that, in addition to the obvious technological gain, the process will be faster and that the set of actions will speed up the availability of a vaccine to Brazilians .
Versamune®-CoV-2FC is the combination of a recombinant SARS-CoV-2 protein, developed by Farmacore, with the nanotechnology of the Versamune® platform, from PDS Biotech, a patented technology for the activation of T cells. ”, Explains Helena .
Still in Brazil, another vaccine is under development to prevent Covid-19 infection. Named Versamune®-CoV-2FC, the vaccine is developed by Farmacore - a company founded in 2005 and located in Ribeirão Preto (SP) - in partnership with PDS Biotechnology Corporation . The preliminary results are expected to be completed by the end of July.
Before being approved, the vaccine must go through important stages until it is approved. After the pre-clinical phase, with tests on animals, there are three phases of tests on humans. The tests need to prove that the vaccine is really safe, that it produces antibodies and protects against the virus.
As the pre-clinical and clinical phase I / IIa trials will be carried out in Brazil, the expectation is that, in addition to the obvious technological gain, the process will be faster and that the set of actions will speed up the availability of a vaccine to Brazilians .
Versamune®-CoV-2FC is the combination of a recombinant SARS-CoV-2 protein, developed by Farmacore, with the nanotechnology of the Versamune® platform, from PDS Biotech, a patented technology for the activation of T cells. ”, Explains Helena .
https://www.vidaeacao.com.br/vacina-da-covid-19-esta-mais-perto-do-que-nunca/